The Government\u2019s current target is for 95% superfast broadband coverage by 2017. There is no target date for 100% superfast coverage at present. However, the Government has recently funded eight projects through the £10 million pilot scheme to explore solutions to provide near universal superfast coverage. <\/em><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1580", "label" : {"_value" : "Biography information for Lord Vaizey of Didcot"}
}
, "answeringMemberConstituency" : {"_value" : "Wantage"}
, "answeringMemberPrinted" : {"_value" : "Mr Edward Vaizey"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T15:18:41.2090253Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "10"}
, "answeringDeptShortName" : {"_value" : "Culture, Media and Sport"}
, "answeringDeptSortName" : {"_value" : "Culture, Media and Sport"}
, "date" : {"_value" : "2014-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Broadband: Copeland"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Culture, Media and Sport, pursuant to the Answer of 17 July 2014 to Question 205697, when he expects 100 per cent of properties in Copeland constituency to have access to superfast broadband.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209979"}
, {"_about" : "http://data.parliament.uk/resources/92590", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/92590/answer", "answerText" : {"_value" : "
NHS England published the list of clinical commissioning groups taking part in the care.data pathfinder stage on 7 October.<\/p>
<\/p>
<\/p>
<\/p>
The clinical commissioning groups are Leeds North, West and South and East, Somerset, West Hampshire and Blackburn with Darwen. Further details can be found at:<\/p>
<\/p>
<\/p>
<\/p>
http://www.england.nhs.uk/2014/10/07/ccgs-care-data-programme/<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T15:08:29.1018846Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Records: Databases"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, when he expects NHS England to publish the list of clinical commissioning groups taking part in the care.data pathfinder stage; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209977"}
, {"_about" : "http://data.parliament.uk/resources/91993", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/91993/answer", "answerText" : {"_value" : "
NHS England created a Specialised Commissioning Taskforce which aims to improve ways of working and to ensure that specialised commissioning is undertaken in the most efficient and effective way possible.<\/p>
<\/p>
<\/p>
<\/p>
My Rt. hon. friend the Secretary of State meets regularly with NHS England to discuss a wide variety of issues. Specialised commissioning was on the agenda at the July NHS Accountability Meeting between NHS England and the Secretary of State.<\/p>
<\/p>
<\/p>
<\/p>
The work of the Taskforce is being carried out with input from key internal and external stakeholders. Within the Taskforce work programme there are specific projects which will need wider engagement and may necessitate public consultation.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "209452"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T17:50:31.857832Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-09-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, whether the NHS England internal taskforce currently reviewing specialised commissioning plans to seek input from internal stakeholders.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209453"}
, {"_about" : "http://data.parliament.uk/resources/91995", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/91995/answer", "answerText" : {"_value" : "
The following table provides data on finished admission episodes (FAEs), finished discharge episodes (FDEs) and FDEs where the patient died, where there is a primary or secondary diagnosis of methadone poisoning, by the requested age groups for the last five years for which data is available.<\/p>
<\/p>
<\/p>
<\/p>
Please note that:<\/p>
<\/p>
- data for buprenorphine ingestion has not been given as it is not possible to identify buprenorphine ingestion from the ICD10 diagnosis scheme available in the Hospital Episode Statistic s (HES) database,<\/p>
<\/p>
- both FAE and FDE are given as the question asks about both admissions and the outcome of the admissions,<\/p>
<\/p>
- admissions, discharges and discharges ending in death are not directly comparable because FAEs and FDEs do not represent the number of patients; as it is possible for an individual to have one or more episodes of care in any given period, while a death record can appear only once,<\/p>
<\/p>
- hospital stays can span year-end so that the numbers of FAEs and FDEs do not necessarily match within any given year,<\/p>
<\/p>
- any person who died without being admitted to hospital would not be counted, and<\/p>
<\/p>
- the ICD-10 codes were used to define 'methadone poisoning' is T40.3 Poisoning by narcotic and psychodysleptics [hallucinogens], methadone<\/p>
<\/p>
<\/p>
<\/p>
Count of (a) finished admission episodes (FAEs)1<\/sup>, (b) finished discharge episodes (FDEs)2<\/sup> and (c) FDEs where the patient died3<\/sup>, with a primary or secondary diagnosis4<\/sup> of methadone poisoning5<\/sup>, by the age groups (i) 0-4 and (ii) 0-17 years, 2008-09 to 2012-136<\/sup><\/p> <\/p>
<\/p><\/td> | 0-4 year olds<\/p><\/td> | 0-17 year olds<\/p><\/td><\/tr> |
FAEs<\/p><\/td> | FDEs<\/p><\/td> | FDEs \u2013 Discharged<\/p> Dead<\/p><\/td> | FAEs<\/p><\/td> | FDEs<\/p><\/td> | FDEs \u2013 Discharged<\/p> Dead<\/p><\/td><\/tr> |
2008-09<\/p><\/td> | 21<\/p><\/td> | 21<\/p><\/td> | 0<\/p><\/td> | 40<\/p><\/td> | 40<\/p><\/td> | 0<\/p><\/td><\/tr> |
2009-10<\/p><\/td> | 22<\/p><\/td> | 22<\/p><\/td> | 0<\/p><\/td> | 68<\/p><\/td> | 68<\/p><\/td> | 0<\/p><\/td><\/tr> |
2010-11<\/p><\/td> | 23<\/p><\/td> | 23<\/p><\/td> | 0<\/p><\/td> | 83<\/p><\/td> | 86<\/p><\/td> | 0<\/p><\/td><\/tr> |
2011-12<\/p><\/td> | 21<\/p><\/td> | 20<\/p><\/td> | 0<\/p><\/td> | 48<\/p><\/td> | 47<\/p><\/td> | 1<\/p><\/td><\/tr> |
2012-13<\/p><\/td> | 13<\/p><\/td> | 14<\/p><\/td> | 0<\/p><\/td> | 31<\/p><\/td> | 32<\/p><\/td> | 0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source:<\/em> Hospital Episode Statistics (HES), Health and Social Care Information Centre<\/p> <\/p> <\/p> <\/p> The following table provides data on the number of deaths due to ingesting methadone or buprenorphine in persons aged (a) under 5 and (b) under 18 for the last five years for which data is available. The data has been divided into deaths in hospital and all deaths so as to capture those persons who were admitted to hospital due to ingesting methadone or buprenorphine, but later died at home.<\/p> <\/p> <\/strong><\/p> <\/p> All deaths and deaths that occurred in a hospital where the underlying cause was poisoning by methadone or buprenorphine, for persons aged (a) under 5 and (b) under 18, England and Wales, deaths registered between 2009-2013 1,2,3<\/sup><\/p> <\/p> <\/p><\/td> | Year<\/p><\/td> | Hospital deaths, under 5<\/p><\/td> | Hospital deaths, under 18<\/p><\/td> | All deaths, under 5<\/p><\/td> | All deaths, under 18<\/p><\/td><\/tr> | Methadone<\/p><\/td> | 2009<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td><\/tr> | <\/p><\/td> | 2010<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td> | 0<\/p><\/td> | 3<\/p><\/td><\/tr> | <\/p><\/td> | 2011<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td> | 0<\/p><\/td> | 8<\/p><\/td><\/tr> | <\/p><\/td> | 2012<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td><\/tr> | <\/p><\/td> | 2013<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td> | 1<\/p><\/td> | 3<\/p><\/td><\/tr> | <\/p><\/td> | <\/p><\/td> | <\/p><\/td> | <\/p><\/td> | <\/p><\/td> | <\/p><\/td><\/tr> | Buprenorphine<\/p><\/td> | 2009<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td><\/tr> | <\/p><\/td> | 2010<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td><\/tr> | <\/p><\/td> | 2011<\/p><\/td> | 0<\/p><\/td> | 1<\/p><\/td> | 0<\/p><\/td> | 2<\/p><\/td><\/tr> | <\/p><\/td> | 2012<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td><\/tr> | <\/p><\/td> | 2013<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td> | 0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source:<\/em> Office for National Statistics (ONS)<\/p> <\/p> <\/p> <\/p> Notes:<\/em><\/p> <\/p> 1. Cause of death was defined using the following International Classification of Diseases, Tenth Revision (ICD-10) codes:<\/p> <\/p> <\/p> <\/p> F11\u2013F16, F18\u2013F19: Mental and behavioural disorders due to drug use (excluding alcohol and tobacco),<\/p> <\/p> X40\u2013X44: Accidental poisoning by drugs, medicaments and biological substances, X60\u2013X64: Intentional self-poisoning by drugs, medicaments and biological substances,<\/p> <\/p> X85: Assault by drugs, medicaments and biological substances, and<\/p> <\/p> Y10\u2013Y14: Poisoning by drugs, medicaments and biological substances, undetermined intent<\/p> <\/p> Deaths were included where the underlying cause was due to drug poisoning and where buprenorphine or methadone was mentioned on the death certificate.<\/p> <\/p> <\/p> <\/p> 2. Figures for England and Wales include deaths of non-residents.<\/p> <\/p> <\/p> <\/p> 3. Figures are for deaths registered, rather than deaths occurring in each calendar year. Due to the length of time it takes to complete a coroner\u2019s inquest, it can take months or even years for a drug-related death to be registered. More details can be found in the 'deaths related to drug poisoning' statistical bulletin: www.ons.gov.uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/england-and-wales---2013/stb---deaths-related-to-drug-poisoning-in-england-and-wales--2013.html#tab-Impact-of-Registration-Delays-on-Drug-Related-Deaths<\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T16:55:51.3735801Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-09-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hospitals: Admissions"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many (a) young people under 18 and (b) children under five have been admitted to hospital after ingesting methadone or buprenorphine in the last five years; and how many such ingestions were fatal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209451"}
, {"_about" : "http://data.parliament.uk/resources/91996", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/91996/answer", "answerText" : {"_value" : " NHS England created a Specialised Commissioning Taskforce which aims to improve ways of working and to ensure that specialised commissioning is undertaken in the most efficient and effective way possible.<\/p> <\/p> <\/p> <\/p> My Rt. hon. friend the Secretary of State meets regularly with NHS England to discuss a wide variety of issues. Specialised commissioning was on the agenda at the July NHS Accountability Meeting between NHS England and the Secretary of State.<\/p> <\/p> <\/p> <\/p> The work of the Taskforce is being carried out with input from key internal and external stakeholders. Within the Taskforce work programme there are specific projects which will need wider engagement and may necessitate public consultation.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "209453"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T17:50:31.7015264Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-09-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what discussions he has had in the last six months with NHS England's Executive Team on the review of specialised commissioning.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209452"}
, {"_about" : "http://data.parliament.uk/resources/91997", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/91997/answer", "answerText" : {"_value" : " United Kingdom clinical guidelines for drug misuse and dependence make clear that doctors treating people with opioid dependence need to make sure that their patients are aware of the risks of their medication, and that they take necessary precautions to avoid it being accidentally taken by others, especially children.<\/p> <\/p> <\/p> <\/p> Clinicians should assess risk to children and, if they suspect a child may be at risk, they must take steps, if necessary immediately, to deal with that risk. This may involve referral to other agencies, in accordance with relevant frameworks and protocols. The assessment may involve looking at the home environment and providing protective measures such as safe storage boxes to ensure medication is beyond the reach of children.<\/p> <\/p> <\/p> <\/p> Monitoring adherence to the clinical guidelines, and taking action where there is a breach, would be the responsibility of the regulatory bodies, the Care Quality Commission and General Medical Council. Local authorities, commissioners, clinical commissioning groups, and local children\u2019s safeguarding boards may set up their own local monitoring arrangements.<\/p> <\/p> <\/p> <\/p> Local authorities have had guidance on developing joint local protocols between the drug and alcohol treatment system and children and family services. The aim of these protocols is to ensure that children are safeguarded through good assessment, clear pathways, information sharing agreements and competent staff.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-15T15:25:13.6060999Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-09-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Rehabilitation"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what monitoring is undertaken to ensure that prescribers carry out adequate safeguarding of children living in families in which someone is undergoing opioid substitution therapy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209450"}
, {"_about" : "http://data.parliament.uk/resources/92007", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/92007/answer", "answerText" : {"_value" : " The UK Strategy for Rare Diseases, published in November 2013, aims to ensure that patients with rare diseases have access to high quality care, including diagnostics, treatments, support and effective drug treatments.<\/p> <\/p> <\/p> <\/p> NHS England is responsible for directly commissioning specialised services accessed by comparatively small numbers of patients and has developed service specifications on a national basis, to ensure that patients can access the same high quality services and treatments regardless of where they live in England.<\/p> <\/p> <\/p> <\/p> From 1 April 2013 the National Institute for Health and Care Excellence (NICE) took responsibility for the evaluation of selected high cost, low volume drugs under its Highly Specialised Technologies Programme. NHS commissioners are legally obliged to provide funding for drugs that have been recommended in NICE technology appraisals or highly specialised technologies evaluations.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-17T09:09:58.8356796Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-09-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps (a) his Department and (b) the National Institute for Health and Care Excellence is taking to ensure that patients have access to drugs and treatments for ultra-rare diseases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "209351"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Mr+Jamie+Reed&_page=1&max-ddpCreated=2014-10-21T21%3A01%3A13.473Z&min-dateTabled=2014-06-09", "page" : 0, "startIndex" : 1, "totalResults" : 44, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|